WHY THE SPRINT TRIAL IS THE "ACCIDENTAL" LONGEVITY SUCCESS OF THE DECADE

SPRINT (Systolic Blood Pressure Intervention Trial) If TAME (Targeting Aging with Metformin) is the future of longevity, SPRINT is the "accidental" longevity trial of the present. It proved that aggressive management of "boring" metrics like blood pressure has massive longevity payoffs. • The Core Finding: SPRINT compared a standard systolic target (140 mmHg) with an intensive target (120 mmHg). The intensive group saw a 25% reduction in cardiovascular events and a 27% reduction in death from any cause. • The "MIND" Connection: A sub-study called SPRINT-MIND followed these participants to see if intensive BP control saved their brains. o 2026 Updates: Long-term follow-up (the "SPRINT-MIND 2020/2025" extensions) confirms that keeping blood pressure at 120 mmHg significantly reduces the risk of Mild Cognitive Impairment (MCI). • The Longevity Lesson: SPRINT reminds us that "vascular aging" is often the bottleneck for human lifespan. By preventing micro-strokes and kidney damage, we effectively extend the period of healthy life.